Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The MMoST Feasibility Trial (Maximising Mobility and Strength Training) has received OCTRU Green Light approval to open to recruitment. We want to conduct a large clinical trial comparing mobility and strength training plus extra protein to training alone in older people with low protein intake. This is a feasibility trial to find out whether it is possible to undertake this trial. 

The feasibility trial aims to recruit 50 people aged 65 years and over who have problems with their walking, or are walking more slowly than before and have low protein intake. All participants will take part in an exercise programme to improve walking and muscle strength. Half of participants will also be given protein drinks to help build their muscles.

Similar stories

OCTRU - delivering answers to important clinical questions

The Oxford Clinical Trials Research Unit (OCTRU) has received NIHR benchmarking results and offers excellent value for money according to the report

Adalimumab is found to be a cost-effective treatment for early-stage Dupuytren’s disease

Researchers at the Kennedy Institute of Rheumatology and Oxford Population Health’s Health Economics Research Centre have found that anti-TNF treatment (adalimumab) is likely to be a cost-effective treatment for people affected by early-stage Dupuytren’s disease.